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The modulation of efﬂux pump functions under ﬂuoroquinolone (FQ) exposure
is of great concern as it could result in occurrence of multidrug-resistant (MDR)
bacterial strains. In this study, MDR mechanism in Pseudomonas aeruginosa induced
via moxiﬂoxacin (MOX) pressure was investigated. After serial MOX [concentration
of 0.5 × the minimum inhibitory concentration (MIC)] exposure, the fully susceptible
P. aeruginosa ATCC 9027 strain has increased its MIC not only toward MOX
(1→128 mg/L) but also to other antibiotics. Furthermore, this MOX-exposed strain did
not revert to antibiotic-sensitive phenotype when being cultured in antibiotic-free
medium for 12 days. No mutation was observed for FQ-target (gyrA and parC) or most
investigated efﬂux regulatory genes (mexT, mexR, and nalC) except nfxB in which a
100-bp deletion was found. This associated with the elevated expression of multidrug
efﬂux pump operon (mexCD-oprJ) which could directly result in MDR phenotype.
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Introduction
Pseudomonas aeruginosa is regarded as one of the major causes of
nosocomial infections worldwide [1]. Treatment of P. aeruginosa infections has
now become more challenging due to its remarkable propensity to rapidly acquire
resistance to a wide range of antibacterial agents [2].
Fluoroquinolone (FQ) class of antimicrobial agents has been increasingly
and extensively used for hospitalized as well as community patients since the late
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1980s due to its potent and broad-spectrum activity against a wide range of Gram-
positive and Gram-negative pathogens [3]. In many countries, FQs are the only
commonly available oral therapy to treat P. aeruginosa infections [4, 5]. FQ
resistance can be considered as one of the consequences to widespread FQ
consumption together with multidrug resistance (MDR), it has arisen at an
alarming rate among P. aeruginosa [4].
The major FQ resistance mechanisms found in non-susceptible clinical
isolates of P. aeruginosa are mutations in the quinolone resistance-determining
regions of the genes encoding the FQ-target proteins (gyrA and parC), and over-
expression of speciﬁc efﬂux pumps [6–8]. It has been additionally shown that efﬂux
pump-mediated FQ resistance may also induce a broader, MDR phenotype [7, 8].
However, recent data have questioned the signiﬁcance of the efﬂux pump activity
in FQ-resistant P. aeruginosa. The aim of this study was to investigate the
resistance mechanisms that are induced by FQs (and other antimicrobials) in
P. aeruginosa via prolonged exposure to the FQ, moxiﬂoxacin (MOX).
Materials and Methods
Bacterial strain and MOX exposure in P. aeruginosa
In this study, P. aeruginosaATCC 9027 strain (susceptible to MOX, 1 mg/L)
was used as starting strain. This strain was serially exposed to MOX concentrations
corresponding to half of the minimum inhibitory concentration (MIC) in Mueller–
Hinton Broth (MHB) [9]. Once P. aeruginosa ATCC 9027 reached a stable
MOX-MIC equilibrium (day 12 of serial exposure), the MOX-resistant strain
(designated as MOX-resistant P. aeruginosa) was sub-cultured repeatedly onto
medium not supplemented with antimicrobials for an additional 12 days in an attempt
to obtain a MOX-susceptible strain (designated as MOX-revertant P. aeruginosa).
The MICs were measured daily. The derived MOX-resistant and MOX-revertant
P. aeruginosa strains were re-identiﬁed as P. aeruginosa by standard bacterial
identiﬁcation methods and 16S rRNA sequencing.
Antimicrobial susceptibility testing
The susceptibility test of three bacterial strains (P. aeruginosa ATCC 9027,
MOX-resistant P. aeruginosa, and MOX-revertant P. aeruginosa) was determined
for nalidixic acid, norﬂoxacin, ciproﬂoxacin, levoﬂoxacin, cephalexin, chloram-
phenicol, lincomycin, erythromycin, and tetracycline using the micro-dilution
method in 96-well plates. All tests were performed in duplicate using MHB and
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were incubated at 37 °C for 18–24 h. The results were interpreted in accordance
with the EUCAST breakpoint tables [10].
Polymerase chain reaction (PCR) ampliﬁcation and sequencing of FQ-target and
efﬂux regulatory genes
To assess the antibiotic resistance mechanism of the induced, non-
reversible, MOX-resistant phenotype, genomic DNA from wild-type P. aerugi-
nosa ATCC 9027 and the two MOX-resistant strains (post-12 days’ MOX sub-
culture and post-12 days’ non-supplemented sub-culture) was extracted. These
DNA extractions were used as templates to amplify the genes encoding the
FQ-target proteins (gyrA and parC) and efﬂux regulatory genes (mexT, mexR,
nalC, and nfxB). Each of PCR reaction contained a volume of 50 μL using TopTaq
Master Mix Kit (Qiagen, Hilden, Germany). The ampliﬁcation conditions are as
previously described [6, 8, 11, 12] and the primers are shown in Table I.
Ampliﬁcation proﬁle of nfxB was as follows: 4 min at 94 °C, followed by 30
cycles (1 min at 94 °C, 45s at 49.3 °C, and 2 min at 72 °C) and a ﬁnal 5 min
elongation at 72 °C. The PCR products were ﬁnally electrophoresed and subjected
to sequencing. The nfxB sequence of P. aeruginosa ATCC 9027, MOX-resistant
P. aeruginosa, and MOX-revertant P. aeruginosa in this study have been submitted
to GenBank under accession nos. KR673324, KR673325, and KR673326.
Reverse transcription-PCR (RT-PCR) analysis
To test the effect of the deletion in the nfxB gene, total RNA extraction and
cDNA synthesis were performed for P. aeruginosa ATCC 9027, MOX-resistant
Table I. List of primers used in this study for PCR and RT-PCR
Gene Forward (5′→3′) Reverse (5′→3′) Reference
Primers for PCR
gyrA GTGTGCTTTATGCCATGAG GGTTTCCTTTTCCAGGTC [6]
parC CATCGTCTACGCCATGAG AGCAGCACCTCGGAATAG [6]
mexT GTAGTAGACGCTGGCCTCCAC GTGAATTCGTCCCACTCGTTC [7]
mexR CATTAGGTTTACTCGGCCAAACC CGCCAGTAAGCGGATACCTG [11]
nalC TCAACCCTAACGAGAAACGCT TCCACCTCACCGAACTGC [12]
nfxB CGATCCTTCCTATTGCACGC AGGGTGATGAACAGTTCGGT This study
Primers for RT-PCR
mexC AGCCAGCAGGACTTCGATACC ACGTCGGCGAACTGCAAC [13]
rpsL GCAACTATCAACCAGCTGGTG GCTGTGCTCTTGCAGGTTGTG [13]
oprJ GTTCCGGGCCTGAATGCCGCTGC TCGCGGCTGACCAGGGTCTGACG [14]
nfxB MUTATION IN MOX-RESISTANT P. AERUGINOSA 247
Acta Microbiologica et Immunologica Hungarica 64, 2017
P. aeruginosa strain, and MOX-revertant P. aeruginosa strain. RT-PCR was
performed to determine the expression of mexC and oprJ. All of the reagents for
these experiments were purchased from Qiagen. The ampliﬁcation proﬁle of RT-
PCR included denaturation at 95 °C for 5 min and followed by 40-cycle steps,
including denaturation for 30 s at 95 °C, annealing for 30 s at 55 °C, elongation for
30 s at 72 °C, and a ﬁnal elongation at 72 °C for 10 min. rpsL was used as an
internal control in all RT-PCR experiments [13]. The band intensities were
quantiﬁed in relation to the rpsL band using ImageJ software (Wayne Rasband,
National Institutes of Health, Bethesda, MD, USA).
Results and Discussion
Serial exposure of P. aeruginosa to MOX
In this study, over the period of sub-culture, there was a sequential increase
in MIC against MOX. After 12 days, a MOX-resistant P. aeruginosa was derived
and had plateaued at an MIC of 128 mg/L; wild-type MIC 1 mg/L (Figure 1).
Notably, our attempt to derive a MOX-susceptible revertant strain was unsuc-
cessful, as the MOX-resistant P. aeruginosa did not revert to a susceptible
phenotype despite 12 days of sub-culture in non-supplemented growth media.
Susceptibility of P. aeruginosa strains
With regard to susceptibility tests, we observed a signiﬁcant increase in MIC
between the wild-type and the MOX-resistant isolate against all antimicrobials:
Figure 1. MOX exposure to P. aeruginosa ATCC 9027 strain. P. aeruginosa ATCC 9027 was
exposed to MOX for 12 days to obtain MOX-resistant P. aeruginosa. This strain was continuously
sub-cultured for another 12 days in antibiotic-free medium with daily examination of MIC (MOX-
revertant strain)
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nalidixic acid (16→128 mg/L), norﬂoxacin (0.125→16 and 8 mg/L for MOX-
resistant and MOX-revertant strains), ciproﬂoxacin (0.0625→8 mg/L), levoﬂoxacin
(0.25→8 mg/L), cephalexin (2→16 mg/L), chloramphenicol (2→16 mg/L), linco-
mycin (1→4 mg/L), erythromycin (2→8 mg/L), and tetracycline (1→32 mg/L).
Notably, there was no difference between the MICs in the primary MOX-resistant
isolate and the secondary MOX-resistant isolate (MOX-revertant strain) after 12
days on non-selective growth media.
These data indicated that after being exposed to MOX, susceptible
P. aeruginosa strain could turn into multidrug-resistant phenotype not only to
other FQs but also to other antibiotics of unrelated groups.
Sequencing results of gyrA, parC, mexT, mexR, nalC, and nfxB
The most common and extensively studied mechanism of FQ resistance is
the alteration of the FQ targets resulting from mutation in one or more of the genes
encoding for gyrase and topoisomerase IV [15]. These enzymes are both tetra-
meric with pairs of two different sub-units: GyrA and GyrB for gyrase and ParC
and ParE for topoisomerase IV. The genes encoding for these sub-units are
chromosomally encoded and named gyrA, gyrB, parC, and parE, respectively.
Until recently, the acquisition of FQ resistance in P. aeruginosa is known to be
mainly due to the mutations in target genes, gyrA and parC [6]. However, after
successful ampliﬁcation and DNA sequencing of amplicons, we found that neither
of the novel strains contained mutations in gyrA and parC in comparison with
wild-type P. aeruginosa ATCC 9027.
The phenomenon of enhanced expression of endogenous efﬂux systems that
restrict the accumulation of drugs inside bacterial cell is well described in
P. aeruginosa [16]. It is common that organisms with enhanced efﬂux activity
have an MDR phenotype [17]. In FQ-resistant P. aeruginosa, mutations are often
found in regulators that can have a dramatic effect on drug efﬂux pump activity
[7, 8]. To test this efﬂux pump activity hypothesis, we ampliﬁed the genes mexT,
mexR, nalC, and nfxB in the three strains and sequenced the resulting amplicons.
No modiﬁcations indicative of changed regulation in mexT, mexR, or nalC have
been found.
Point mutations in nfxB were frequently found in clinical P. aeruginosa
isolates and involved in the reduction of the susceptibility to FQs, especially for
ciproﬂoxacin [18–20]. In this study, we identiﬁed a 100-bp deletion in nfxB genes
in the MOX-resistant and MOX-revertant strains from nucleotide position
196→296 (GenBank accession no. KR673324). This seemed strongly related to
a high level of MOX resistance as no signiﬁcant mutations on principal genes
involving in drug resistance were found. This ﬁnding supported Monti et al.’s [21]
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study which showed that nfxB mutations including substitution, 1-bp deletion and
insertion, >1-bp deletion, and duplication mutations were also linked to FQ
(ciproﬂoxacin) resistance in P. aeruginosa.
Disruption of nfxB resulting in elevated expression of multidrug efﬂux pumps
nfxB is a repressor of mexCD-oprJ a multidrug efﬂux operon of
P. aeruginosa [22, 23]. Loss of function mutations in nfxB is typically associated
with an over-expression of mexCD-oprJ [9, 24]. However, occurrence of mexCD-
oprJ-expressing mutants was very rare in a clinical setting [20, 25, 26]. To assess
whether the 100 bp within nfxB was inﬂuencing mexCD-oprJ expression, we
determined the expression of mexC and oprJ by RT-PCR. As predicted, the nfxB
deletion in the MOX-resistant and MOX-revertant P. aeruginosa strains induced
an increase in expression of both mexC and oprJ (Figure 2).
Figure 2. Comparison of mexC and oprJ expression between initial P. aeruginosa ATCC 9027 and
MOX-exposed strains. Expression ofmexC (A) and oprJ (B) was assessed in initial P. aeruginosa (1),
MOX-resistant P. aeruginosa (2), and MOX-revertant P. aeruginosa (3). rpsL was used as internal
control. The band intensities were quantiﬁed by ImageJ software
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Conclusion
In conclusion, we report that disruption of nfxB gene plays an important role
in the development of FQ resistance and an MDR phenotype in P. aeruginosa. In
this study, P. aeruginosa can gain resistance to FQs and other antibiotics via
mutations in intrinsic regulatory pathways. Furthermore, the type of gene regula-
tion containing this disruption seems not reversible resulting in stable MDR
phenotype. The mechanism underlying the resistance to antibiotics of other classes
is currently unknown but could be of clinical signiﬁcance in an era of diminishing
antibiotic treatment options for P. aeruginosa infection.
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